Sweden’s Hansa Biopharma AB (formerly Hansa Medical) has appointed Donato Spota as its new chief financial officer, effective 15 May 2019. He will be joining from Basilea Pharmaceutica AG where he has been CFO for the past five years. Hansa’s lead product is an antibody-degrading enzyme in late-stage clinical development to enable high-risk patients receive kidney transplants. Mr Spota has more than 20 years of international pharmaceutical industry experience including work in strategic finance, investor relations and international capital market transactions.
Hansa announced the appointment on 7 February 2019.
Copyright 2019 Evernow Publishing Ltd